Matches in SemOpenAlex for { <https://semopenalex.org/work/W1536897886> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W1536897886 endingPage "72" @default.
- W1536897886 startingPage "66" @default.
- W1536897886 abstract "In a 4-week randomized placebo-controlled clinical trial we investigated the effect of 300 mg Blueberin, a phytomedicine containing 250 mg Blueberry leaves (Vaccinium arctostaphylos L, Ericaceae) extract providing minimum 50 mg 3,4-caffeoylquinic (chlorogenic) acid, and 50 mg myricetin, on fasting plasma glucose, alanine aminotransferases (ALT), aspartate aminotransferases (AST), glutamyltransferase (GGT) enzymes levels, and serum inflammatory C-Reactive proteins (CRP) in forty-two volunteer subjects (46+/-15 year of age, BMI 25+/-3 kgs/(m2)) diagnosed with Type 2 diabetes. During the 4-week trial, the Blueberin supplement was administered three times per day, 15-30 minutes prior to a meal along with 100 ml of water. Results of this trial revealed that the supplementation of Blueberin reduced fasting plasma glucose from 143+/-5,2mg/L to 104+/-5,7 mg/L (p<0,001), whereas there was no statistically significant changes in the Placebo group from 138+/-4,8 mg/L to 126+/-5,1mg/L (p>0,05). The reduction of fasting glucose was correlated with the reduction of serum CRP and in the Blueberin group from 5,18+/-1,4 mg/l to 2,14+/-1,8 mg/L (p<0,05), whereas in the Placebo group CRP levels were not significantly reduced from 5,11+/-1,7 mg/l to 4,94+/-1,1mg/L (p>0,05). Furthermore, the Blueberin also significantly reduced the levels of plasma enzymes ALT, AST and GGT, indicating that, in addition to anti-diabetes effects, the Blueberin also possess pharmacologically relevant anti-inflammatory properties." @default.
- W1536897886 created "2016-06-24" @default.
- W1536897886 creator A5004353457 @default.
- W1536897886 creator A5046520977 @default.
- W1536897886 creator A5050837946 @default.
- W1536897886 creator A5070486676 @default.
- W1536897886 date "2006-12-01" @default.
- W1536897886 modified "2023-10-12" @default.
- W1536897886 title "Effect of Blueberin on fasting glucose, C-reactive protein and plasma aminotransferases, in female volunteers with diabetes type 2: double-blind, placebo controlled clinical study." @default.
- W1536897886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17261891" @default.
- W1536897886 hasPublicationYear "2006" @default.
- W1536897886 type Work @default.
- W1536897886 sameAs 1536897886 @default.
- W1536897886 citedByCount "25" @default.
- W1536897886 countsByYear W15368978862012 @default.
- W1536897886 countsByYear W15368978862013 @default.
- W1536897886 countsByYear W15368978862014 @default.
- W1536897886 countsByYear W15368978862015 @default.
- W1536897886 countsByYear W15368978862016 @default.
- W1536897886 countsByYear W15368978862018 @default.
- W1536897886 countsByYear W15368978862019 @default.
- W1536897886 countsByYear W15368978862020 @default.
- W1536897886 countsByYear W15368978862021 @default.
- W1536897886 countsByYear W15368978862022 @default.
- W1536897886 countsByYear W15368978862023 @default.
- W1536897886 crossrefType "journal-article" @default.
- W1536897886 hasAuthorship W1536897886A5004353457 @default.
- W1536897886 hasAuthorship W1536897886A5046520977 @default.
- W1536897886 hasAuthorship W1536897886A5050837946 @default.
- W1536897886 hasAuthorship W1536897886A5070486676 @default.
- W1536897886 hasConcept C126322002 @default.
- W1536897886 hasConcept C134018914 @default.
- W1536897886 hasConcept C142724271 @default.
- W1536897886 hasConcept C204787440 @default.
- W1536897886 hasConcept C27081682 @default.
- W1536897886 hasConcept C2776768635 @default.
- W1536897886 hasConcept C2776914184 @default.
- W1536897886 hasConcept C2776971262 @default.
- W1536897886 hasConcept C2777180221 @default.
- W1536897886 hasConcept C2778345441 @default.
- W1536897886 hasConcept C2781195455 @default.
- W1536897886 hasConcept C555293320 @default.
- W1536897886 hasConcept C6557445 @default.
- W1536897886 hasConcept C71924100 @default.
- W1536897886 hasConcept C86803240 @default.
- W1536897886 hasConceptScore W1536897886C126322002 @default.
- W1536897886 hasConceptScore W1536897886C134018914 @default.
- W1536897886 hasConceptScore W1536897886C142724271 @default.
- W1536897886 hasConceptScore W1536897886C204787440 @default.
- W1536897886 hasConceptScore W1536897886C27081682 @default.
- W1536897886 hasConceptScore W1536897886C2776768635 @default.
- W1536897886 hasConceptScore W1536897886C2776914184 @default.
- W1536897886 hasConceptScore W1536897886C2776971262 @default.
- W1536897886 hasConceptScore W1536897886C2777180221 @default.
- W1536897886 hasConceptScore W1536897886C2778345441 @default.
- W1536897886 hasConceptScore W1536897886C2781195455 @default.
- W1536897886 hasConceptScore W1536897886C555293320 @default.
- W1536897886 hasConceptScore W1536897886C6557445 @default.
- W1536897886 hasConceptScore W1536897886C71924100 @default.
- W1536897886 hasConceptScore W1536897886C86803240 @default.
- W1536897886 hasIssue "141" @default.
- W1536897886 hasLocation W15368978861 @default.
- W1536897886 hasOpenAccess W1536897886 @default.
- W1536897886 hasPrimaryLocation W15368978861 @default.
- W1536897886 hasRelatedWork W1966333843 @default.
- W1536897886 hasRelatedWork W2045367862 @default.
- W1536897886 hasRelatedWork W2071105793 @default.
- W1536897886 hasRelatedWork W2086894460 @default.
- W1536897886 hasRelatedWork W2096973883 @default.
- W1536897886 hasRelatedWork W2122850211 @default.
- W1536897886 hasRelatedWork W2127396703 @default.
- W1536897886 hasRelatedWork W2153389651 @default.
- W1536897886 hasRelatedWork W2157476818 @default.
- W1536897886 hasRelatedWork W2462691803 @default.
- W1536897886 isParatext "false" @default.
- W1536897886 isRetracted "false" @default.
- W1536897886 magId "1536897886" @default.
- W1536897886 workType "article" @default.